Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.
Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE. Moss RB, et al. Among authors: milla c. Chest. 2004 Feb;125(2):509-21. doi: 10.1378/chest.125.2.509. Chest. 2004. PMID: 14769732 Clinical Trial.
Cystic fibrosis pulmonary exacerbations.
Ferkol T, Rosenfeld M, Milla CE. Ferkol T, et al. J Pediatr. 2006 Feb;148(2):259-64. doi: 10.1016/j.jpeds.2005.10.019. J Pediatr. 2006. PMID: 16492439 Review. No abstract available.
Recent advances in cystic fibrosis.
Milla CE, Moss RB. Milla CE, et al. Curr Opin Pediatr. 2015 Jun;27(3):317-24. doi: 10.1097/MOP.0000000000000226. Curr Opin Pediatr. 2015. PMID: 25888148 Review.
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group. Ratjen F, et al. Among authors: milla ce. Lancet Respir Med. 2017 Jul;5(7):557-567. doi: 10.1016/S2213-2600(17)30215-1. Epub 2017 Jun 9. Lancet Respir Med. 2017. PMID: 28606620 Free article. Clinical Trial.
Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B; Cystic Fibrosis Foundation Therapeutics Development Network. Deterding R, et al. Among authors: milla c. Pediatr Pulmonol. 2005 Apr;39(4):339-48. doi: 10.1002/ppul.20192. Pediatr Pulmonol. 2005. PMID: 15704203 Clinical Trial.
184 results